Home / Ophthalmology

Neovascular eye disease

An injectable hydrogel, proposed to replace monthly injections.

Ophthalmology

SAPHTx: an injectable hydrogel for the back of the eye

The proposed solution is a cost-effective, long lasting, and injectable hydrogel called SAPHTx. This hydrogel is composed exclusively of naturally occurring amino acids engineered to include an anti-angiogenic peptide.

The intent is a treatment that lasts, delivered by injection, so that patients are not returning every month for an anti-VEGF dose.

LENS RETINA INJECTION One injection; the hydrogel forms in place and releases peptide over time.
Intravitreal delivery, drawn for this rebuild.

The problem

Why another injection

Two leading causes of blindness

Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are leading causes of blindness worldwide, and the burden falls on older, diabetic and under-represented populations.

Abnormal vessel growth

Proliferation of maladaptive blood vessels on the retina characterises these posterior-segment neovascular diseases.

Monthly injections

The standard of care is monthly intraocular injections of VEGF inhibitors — costly, uncomfortable, and carrying a risk of endophthalmitis.

Lasers are not the answer

Laser ablation is not preferred: scarring, disease recurrence, invasiveness and higher inpatient costs.

Macro photograph of a human eye
Not a patient, and not a retinal scan: a stock macro photograph, CC BY 2.0.

Market

A market measured in billions

The total market for AMD is estimated to be greater than $5 billion and is expected to reach $11.5 billion by 2026, with an 8.9% compound annual growth rate. Key players include Lucentis, Eylea, Avastin and Visudyne, with others in clinical trials.

Figures as published in the 2019 abstract, attributed to that source.

Where this programme stands

It was presented as a proposed solution in a 2019 Biomaterials Society abstract from the New Jersey Institute of Technology. No clinical trial, regulatory filing or approval is claimed for it anywhere on this site.

The platform behind it